立体定向磁共振引导自适应放疗治疗盆腹腔异时性寡转移的四年可行性及安全性
这项1/2期单臂前瞻性临床试验纳入10例盆腹腔异时性寡转移(≤7 cm、≤3个活跃病灶)的实体瘤患者,全部接受40 Gy/5次SMART。中位随访4.22年,仅3例出现急性1级毒性,无更高分级或晚期毒性;4年局部控制率和总生存率均为90%,4年无远处进展生存率为20%。
要点
- SMART治疗盆腹腔异时性寡转移可行且安全,仅见急性1级毒性。
- 4年局部控制率和总生存率均为90%,无远处进展生存率为20%。
- 2例患者(前列腺癌和肾细胞癌各1例)SMART后超4年无病且未再治疗。
核心结论
- 中位随访4年余,该小样本前瞻性试验显示SMART转移灶定向治疗盆腹腔异时性寡转移毒性低,支持其可行性。
研究设计与样本
- 1/2期单臂前瞻性临床试验,纳入10例盆腹腔异时性淋巴结或软组织转移的实体瘤患者,病灶最大径≤7 cm且活跃病灶≤3个。
- 所有患者接受40 Gy分5次SMART,按CTCAE v5评估急性毒性并随访1年,通过病历回顾分析晚期毒性和临床结局。
主要发现
- 8例前列腺癌和2例肾细胞癌患者均按方案成功完成SMART,无并发症。
- 3例出现急性1级毒性,无更高分级毒性或晚期毒性。
- 4年局部控制率和总生存率均为90%,4年无远处进展生存率为20%。
- 2例患者(前列腺癌、肾细胞癌各1例)在SMART后超过4年无疾病证据,且未接受进一步系统或局部治疗。
关键数值与推荐
- 入组标准:实体瘤盆腹腔异时性淋巴结或软组织转移,最大径≤7 cm,活跃病灶≤3个。
- 放疗剂量:40 Gy分5次。
- 毒性分级采用CTCAE v5,急性毒性按方案随访1年。
临床怎么用
- 对于盆腹腔异时性寡转移(≤7 cm、≤3个活跃病灶),SMART可作为毒性较低的转移灶定向治疗选择。
- 治疗前应确认病灶符合大小和数量限制,并按40 Gy/5次方案实施。
局限性
- 样本量小(仅10例),为单臂试验,无对照组。
- 晚期毒性和临床结局通过病历回顾分析,可能存在回顾性偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Metachronous oligometastases may represent a favorable disease state for local therapy after prior curative treatment. Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) provides precise targeting of nodal and soft tissue metastases. The primary objective was to assess the feasibility and safety of SMART for abdominopelvic metachronous oligometastases. Secondary objectives included assessing rates of toxicities and evaluating local control (LC). METHODS AND MATERIALS: Ten patients were enrolled with solid tumor metachronous abdominopelvic nodal or soft tissue metastases, ≤7 cm in maximal diameter, and ≤3 sites of active disease. All patients received 40 Gy in 5 fractions. Acute toxicities were graded per Common Terminology Criteria for Adverse Events v5 per-protocol follow-up over 1 year. Late toxicities and clinical outcomes were elucidated by chart review. LC, distant progression-free survival, and overall survival were analyzed using the Kaplan-Meier Method. RESULTS: Eight patients with prostate cancer and 2 with renal cell carcinoma were enrolled in the study. All patients were successfully treated with SMART per-protocol without complications. The median follow-up after SMART was 4.22 years. Three patients experienced acute grade 1 toxicities; there were no higher grade or late toxicities. Among these 10 patients, 4-year LC and overall survival were both 90%, and 4-year distant progression-free survival was 20%. Two patients (1 prostate cancer, 1 renal cell carcinoma) remain with no evidence of disease, each at over 4 years following SMART and without receiving further systemic or local therapies. CONCLUSIONS: With 4 years median follow-up, this small prospective trial reports low toxicity, supporting the feasibility of SMART metastasis-directed therapy for metachronous oligometastases with minimal risk of acute or late toxicity.
引用
- Howard TP, Walburn T, Benham G, et al. Four-Year Feasibility and Safety Results of a Phase 1/2 Single-Arm Prospective Clinical Trial of Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy for Metachronous Oligometastatic Abdominopelvic Lymph Node and Soft Tissue Metastases. Int J Radiat Oncol Biol Phys. 2026. PMID: 41529791. doi:10.1016/j.ijrobp.2026.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。